Cardamonin

Research use only, not for human use.

Cardamonin (Cardamomin) is a chalcone isolated from Alpiniae katsumadai. It has anticancer, anti-inflammatory, antimicrobial, antioxidant and anti-diabetic activities.

Cardamonin can be found from cardamom, and target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities.

Cardamonin (5-40 μM, 24 or 48 h) treatment inhibits gastric cancer cell growth.Cardamonin (10-30 μM, 24 or 48 h) treatment can regulate the expression of apoptosis relative protein.Cardamonin (10-30 μM, 24 or 48 h) treatment can inhibit STAT3 phosphorylation.Cardamonin (0-100 μM, 24 h) treatment improves the anti-oxidative capacity in HL-1 cells.Cell Viability Assay Cell Line:AGS, MGC-803, BGC-823 cells Concentration:5, 10, 20, 30, 40 μM Incubation Time:24 or 48 hours Result:Inhibited cell growth in a concentration-dependent manner.Western Blot Analysis Cell Line:AGS, MGC-803, BGC-823 cells Concentration:10, 20, 30 μM Incubation Time:24 or 48 hours Result:Down-regulated Bcl-2, increased Bax protein expression, and increased the protein expression levels of Caspase-3.Western Blot Analysis Cell Line:AGS cells Concentration:10, 20, 30 μM Incubation Time:24 or 48 hours Result:Suppressed the phosphorylation level of STAT3.Western Blot Analysis Cell Line:HL-1 cells Concentration:0, 25, 50, 100 μM Incubation Time:24 hours Result:Showed anti-oxidant effects in doxorubicin-stimulated cardiomyocytes.

Cardamonin (oral gavage; 20, 40 or 80 mg/kg; once) treatments alleviates doxorubicin-induced cardiotoxicity and inhibits apoptosis in doxorubicin-challenged mice.Animal Model:Male C57BL/6 J mice (8 weeks old, 20-22 g) Dosage:20, 40 or 80 mg/kg Administration:Oral gavage; 20, 40 or 80 mg/kg; once Result:Rescued the reduction of LVEF% and LVFS% by doxorubicin, reduced the increasement of serum LDH, CK-MB and Tn-T levels by doxorubicin in a dose-dependent manner, improved doxorubicin-induced histological changes, and attenuated collagen accumulation in cardiac sections by doxorubicin in a dose-dependent manner.Animal Model:Male C57BL/6 J mice (8 weeks old, 20-22 g) Dosage:20, 40 or 80 mg/kg Administration:Oral gavage; 20, 40 or 80 mg/kg; once Result:Rescued Bcl-2, and inhibited Bax and Caspase-3 cleavage in heart tissues from doxorubicin-challenged mice.

——

Membrane Transporter/Ion Channel

TRP/TRPV Channel

TRP/TRPV Channel | mTOR | Akt | STAT | COX | Wnt/beta-catenin | Antioxidant | NF-κB

——

——

18956-16-6

270.28

C16H14O4

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (462.48 mM; Ultrasonic )

O=C(C=CC=1C=CC=CC1)C=2C(O)=CC(O)=CC2OC

——

(-20℃)

With Ice Pack

≥ 2 years